Fig. 2: Any adverse events in healthy pneumococcal vaccine–naïve infants. | npj Vaccines

Fig. 2: Any adverse events in healthy pneumococcal vaccine–naïve infants.

From: Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

Fig. 2

Forest Plot of Meta-Analysis Comparing PCV15 and PCV13: Risk of any adverse events in healthy pneumococcal vaccine–naïve infants. CI confidence interval, G1 group1: G5 group 5, PCV15 15-valent pneumococcal conjugate vaccine, PCV13 13-valent pneumococcal conjugate vaccine, RR risk ratioEvents refers to the number of participants with any adverse event after any dose of PCV15 or PCV13. Total refers to the number of participants in the safety population of the PCV15 and PCV13 group. Banniettis 2022 Cohort 1: participants aged 7–11 months at the time of receiving the first dose. Bili 2023 G5 vs. G1: Only Group 5 (PCV15) and Group 1 (PCV13) were included in the meta-analysis. Groups 3 and 4, which received mixed schedules (PCV13/PCV15), were not considered. Platt 2020 Lot 1 + 2: The study investigator compared two different PCV15 lots (unique identifiers assigned to specific vaccine doses) with PCV13. We combined the safety data from the PCV15 Lot 1 and Lot 2 groups.

Back to article page